Drug intelligence / Profile preview

fluticasone furoate + vilanterol + prednisolone + tezepelumab

Development stage: Preclinical
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Inhalation, Oral, Subcutaneous

Overview

This is a combination therapy consisting of four medications used together to treat severe asthma and chronic eosinophilic pneumonia. The combination includes fluticasone furoate (an inhaled corticosteroid), vilanterol (a long-acting beta2-adrenergic agonist), prednisolone (an oral corticosteroid), and tezepelumab (a thymic stromal lymphopoietin antagonist). This specific combination has been documented in the treatment of severe asthma with chronic eosinophilic pneumonia, showing marked improvement in symptoms, pulmonary function, and reduction in eosinophil counts.

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on fluticasone furoate + vilanterol + prednisolone + tezepelumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluticasone furoate + vilanterol + prednisolone + tezepelumab.

Explore the full profile